Persistent subjective tinnitus Persistent subjective tinnitus Tinnitus handicap inventory VAS tinnitus
Conditions
Interventions
The subjects will be administered 5 mg of Clorazepate dipotassium orally, one tablet daily after dinner. This dosage will be maintained for a duration of 3 months. Evaluations will be conducted three
Active Comparator Drug,Placebo Comparator Drug
Clorazepate,Placebo
Sponsors
Faculty of medicine, Khon Kaen university
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 to 75 years 2. Persistent subjective tinnitus for at least 6 months 3. Scored 38 or higher, moderate severity on the Thai Tinnitus Handicap Inventory
Exclusion criteria
Exclusion criteria: 1. Patients with contraindications to benzodiazepines, a history of drug allergies, angle-closure glaucoma, or who are pregnant. 2. Patients with pre-existing psychiatric conditions, specifically anxiety and depressive disorders. 3. Patients currently receiving treatment with antidepressants, anticonvulsants, or CNS depressants such as opioids. 4. Patients at high risk of injury or danger should drowsiness occur from medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| THI score at 1 month, 2 month and 3 month after treatment Tinnitus handicap inventory | — |
Secondary
| Measure | Time frame |
|---|---|
| VAS tinnitus at 1 month, 2 month and 3 month after treatment Visual analog scale,Side effect of clorazepate at 1 month, 2 month and 3 month after treatment Data record form | — |
Countries
Thailand
Contacts
Public ContactChanakan Leelalertlauw
Khon Kaen University
Outcome results
None listed